生物仿制药
生物等效性
德诺苏马布
药代动力学
医学
药理学
最大值
不利影响
置信区间
随机对照试验
肿瘤科
内科学
骨质疏松症
作者
Hong Zhang,Cuiyun Li,Jingrui Liu,Min Wu,Xiaojiao Li,Xiaodong Zhu,Qianqian Li,Boguang Wang,Yanhong Mao,Yanhua Ding,Qinglong Jin
标识
DOI:10.1080/13543784.2021.1863371
摘要
(2021). Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects. Expert Opinion on Investigational Drugs: Vol. 30, No. 2, pp. 185-192.
科研通智能强力驱动
Strongly Powered by AbleSci AI